Lead Product(s) : Invimestrocel
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Athersys
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MultiStem® cell therapy (invimestrocel) is a patented regenerative medicine product candidate in clinical development that has shown the ability to promote tissue repair and healing in a variety of ways, such as through the production of therapeutic fac...
Product Name : MultiStem
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
May 20, 2022
Lead Product(s) : Invimestrocel
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Athersys
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Invimestrocel
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Athersys
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Healios reported that last patient in its Phase 2/3 TREASURE study, evaluating MultiStem, a patented regenerative medicine product for the treatment of ischemic stroke, completed the 365-day follow-up visit.
Product Name : MultiStem
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
April 04, 2022
Lead Product(s) : Invimestrocel
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Athersys
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Invimestrocel
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Athersys
Deal Size : Inapplicable
Deal Type : Inapplicable
Athersys Announces Restructuring and Management Changes to Focus on Its Existing Clinical Programs
Details : MultiStem® cell therapy (invimestrocel) is patented regenerative medicine product has shown ability to promote tissue repair and healing in a variety of ways, such as through production of therapeutic factors in response to signals of inflammation and t...
Product Name : MultiStem
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
February 06, 2022
Lead Product(s) : Invimestrocel
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Athersys
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Invimestrocel
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Athersys
Deal Size : Inapplicable
Deal Type : Inapplicable
HEALIOS K.K. Completes Enrollment in the TREASURE Study of MultiStem Treatment
Details : The TREASURE study is a placebo-controlled, double-blind, phase 2/3 trial designed to confirm the efficacy and safety of MultiStem (HLCM051) in treating patients with ischemic stroke.
Product Name : MultiStem
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
October 08, 2021
Lead Product(s) : Invimestrocel
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Athersys
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Prasugrel Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : This application for prasugrel HCl is based on the results of a phase 3 study in thrombotic stroke patients in Japan (PRASTRO-III study), as well as other phase 3 studies in Japan targeting patients with ischemic cerebrovascular disease (PRASTRO-I and PR...
Product Name : Effient
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 15, 2020
Lead Product(s) : Prasugrel Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Prasugrel Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The study was carried out in a double-blind comparative manner to examine the efficacy and safety of prasugrel and clopidogrel in 234 thrombotic stroke patients with one or more risk factors for the recurrence of ischemic stroke.
Product Name : Effient
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 21, 2020
Lead Product(s) : Prasugrel Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bempedoic Acid,Ezetimibe
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Positive CHMP opinions are based on a global clinical trial programme demonstrating consistent LDL-C lowering across a range of patient populations.
Product Name : Nustendi
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 31, 2020
Lead Product(s) : Bempedoic Acid,Ezetimibe
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable